| Name | KR-33493 |
| Description | KR-33493 is a FAS-associated factor 1 (FAF1) inhibitor and can be used in studies about Parkinson's disease. |
| In vitro | Bodyweight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups of either sex are found in hematology, serum biochemistry, and urinalysis. In dogs administrated KR-33493 for 2 weeks, red blood cell count (RBC) value in males is significantly higher at the 1000 mg/kg/day dose than that of the control group (i.e., 6.96±0.323 vs. 6.12±0.418). However, the change of RBC is recovered after the end of the administration period. |
| In vivo | In Sprague-Dawley (SD) rats, KR-33493(500 and 1000 mg/kg; oral) shows no significant changes including Bodyweight changes, hematology, serum biochemistry, and urinalysis. In dogs, red blood cell count value in males is significantly higher at the 1000 mg/kg/day dose with KR-33493 and is recovered after the end of the administration period[1]. |
| Storage | store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 28 mg/mL (60.8 mM)
|
| Keywords | KM 819 | KR 33494 | KR33493 | KR-33493 | KR 33493 | KM819 | KR33494 |
| Inhibitors Related | Araloside A | Marginatoxin |
| Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max |
United States
